Antion launch new technology for cancer and tumour treatments
Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases with significant unmet need, including a form of blood cancer.
The company’s new miCAR platform has the potential to provide an off-the-shelf treatment option for patients; this is instead of the traditional method for CAR T-cell therapies, which involves extracting the patient’s cells, and longer manufacturing steps.
The miCAR technology will be used primarily to find therapies in multiple myeloma, a cancer of the bone marrow, as well as haematological malignancies and solid tumours. Antion also hopes to use it to target infectious diseases such as HIV and COVID-19.
The miCAR construct is based on Antion’s Therapeutic MiniGene technology, a synthetic microRNA construct which has the ability to accurately silence multiple target genes simultaneously.
The company were able to create allogeneic miCAR T-cells with the ability to simultaneously silence multiple genes and express therapeutic proteins in a single manufacturing step. These T-cells are designed to overcome the immunosuppressive tumour microenvironment, achieving increased persistence and improved safety.
Dr Sven Kili, CEO of Antion Biosciences, said: “The cell and gene therapy environment is maturing fast and we’ve seen numerous drug approvals over the last few years that have changed the treatment paradigm for patients all over the world.
“Our miCAR technology builds on the existing work carried out on autologous CAR T-cell therapies and provides patients a much-needed, allogeneic therapy option which will make a positive difference to safety, efficacy and the ease with which patients are treated.
He continued: “I’m extremely excited to be leading the Antion team as we begin progressing our miCAR T-cell therapy for multiple myeloma, as well as other indications, to the next development stages.”
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …